BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nobex Corporation To Reacquire Rights And Data From Alliance With GlaxoSmithKline (GSK) On Modified Insulin Products


10/19/2005 5:10:45 PM

RESEARCH TRIANGLE PARK, N.C., Nov. 14 /PRNewswire/ -- NOBEX announced today that it will reacquire all rights, intellectual property, data, and all other assets related to its modified insulin molecules for all routes of delivery that had been licensed to GSK or produced by GSK during the parties' 17-month alliance. This transaction followed a decision by GSK to end the alliance based on internal business reasons.

The parties are engaged in a cooperative process to transition the R&D program to NOBEX, including ongoing studies that GSK will fund to completion.

NOBEX will get all of the research results from the collaboration that GSK largely funded, providing additional data to NOBEX that will assist in developing products, including new modified insulin molecules for several indications and non-oral routes of delivery for the treatment of diabetes.

"We have seen important advances in the technology and the drug development program during our period of work with GSK and remain confident of the commercial potential of our modified insulin products," stated Dr. Christopher H. Price, President & CEO of NOBEX. "Although we are disappointed with GSK's business decision not to pursue the insulin program with NOBEX, we are enthusiastic to resume our insulin program and to seek a new partner with strong interests in metabolic disease."

On its own or with a another partner, NOBEX intends to resume research and development of potential insulin products based on its technology, including the lead HIM2 oral insulin drug that had been advanced into Phase II trials by NOBEX prior to the alliance with GSK.

About Oral Insulin

Insulin has been commercially available only in injectable forms since its introduction into medicine about 75 years ago. NOBEX has developed a modified insulin under its patented polymer technology that resists enzymatic degradation of insulin in the body and is rapidly absorbed into the bloodstream after the patient takes an oral dose. The convenience of an oral insulin product would be of significant benefit to patients and may increase their compliance in taking insulin, so important to the long-term control of diabetes.

NOBEX oral insulin is absorbed across the intestinal wall and follows the same pathway as insulin normally released by the pancreas, entering the body by a blood vessel known as the portal vein and carried immediately to the liver. Insulin from the pancreas or from oral delivery arrives at the liver in a large pulse and may activate the liver to participate in the control of blood glucose. The properly activated liver is thought to stimulate a number of metabolic actions that could help reduce the complications of diabetes, such as vascular disease.

About Diabetes

The pancreas in the patient with type 1 diabetes has lost the ability to produce insulin. To control blood glucose, insulin must be administered several times per day. In type 2 patients, the pancreas can produce insulin. However as the disease progresses, it does not provide enough insulin at the proper time for effective control of blood glucose. The primary metabolic disorder in type 2 diabetes is insulin resistance, which is often treated with insulin sensitizing agents to help patients use more effectively the insulin their bodies naturally produce. If left untreated, a patient with diabetes can develop a number of debilitating medical complications in addition to the inability to control blood sugar. The estimated cost of diabetes and its complications to the U.S. economy is approaching $100 billion per year.

About NOBEX

NOBEX Corporation is a privately held drug product development company that specializes in medicinal chemistry applied to optimizing the delivery of therapeutic drugs. The company has advanced three products into clinical study, including the oral calcitonin Oratonin(TM) tablet for treating the pain of vertebral fractures, the APAZA compound, an oral tablet for inflammatory bowel disease, and insulin in an oral tablet for diabetes. NOBEX has several other products in preclinical development on its own and with partners or collaborators including Pfizer, Duke University, and the Mayo Clinic. For more information, visit http://www.nobexcorp.com/.

Contacts: NOBEX Corporation Christopher Price, Ph.D. Chief Executive Officer (919) 474-0507 Euro RSCG Life NRP Emily Poe (212) 845-4266

NOBEX Corporation

CONTACT: Christopher Price, Ph.D., Chief Executive Officer of NOBEXCorporation, +1-919-474-0507; or Emily Poe of Euro RSCG Life NRP,+1-212-845-4266, for NOBEX Corporation



Read at BioSpace.com

   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES